Patents Assigned to Gilead Pharmasset LLC
-
Patent number: 11203599Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.Type: GrantFiled: February 21, 2020Date of Patent: December 21, 2021Assignee: Gilead Pharmasset LLCInventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
-
Patent number: 11192875Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.Type: GrantFiled: January 16, 2020Date of Patent: December 7, 2021Assignee: Gilead Pharmasset LLCInventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May, Katie Ann Brown, Christopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer
-
Patent number: 11116783Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: June 16, 2020Date of Patent: September 14, 2021Assignee: Gilead Pharmasset LLCInventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
-
Patent number: 10912814Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: June 1, 2017Date of Patent: February 9, 2021Assignee: Gilead Pharmasset LLCInventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
-
Patent number: 10807990Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 11, 2018Date of Patent: October 20, 2020Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
-
Publication number: 20200323894Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.Type: ApplicationFiled: June 1, 2017Publication date: October 15, 2020Applicants: Gilead Pharmasset LLC, Gilead Pharmasset LLCInventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
-
Patent number: 10800789Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: December 4, 2018Date of Patent: October 13, 2020Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Jeromy J. Cottell, John O. Link, Teresa Alejandra Trejo Martin
-
Patent number: 10603318Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.Type: GrantFiled: May 10, 2019Date of Patent: March 31, 2020Assignee: Gilead Pharmasset LLCInventors: Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Kyla Ramey, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
-
Patent number: 10604530Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.Type: GrantFiled: December 18, 2017Date of Patent: March 31, 2020Assignee: Gilead Pharmasset LLCInventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
-
Patent number: 10577359Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-ß-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.Type: GrantFiled: February 6, 2017Date of Patent: March 3, 2020Assignee: Gilead Pharmasset LLCInventors: Byoung-Kwon Chun, Jinfa Du, Suguna Rachakonda, Peiyuan Wang
-
Patent number: 10456414Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.Type: GrantFiled: January 6, 2017Date of Patent: October 29, 2019Assignee: Gilead Pharmasset LLCInventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang
-
Patent number: 10344019Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 30, 2015Date of Patent: July 9, 2019Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James G. Taylor, Chinh Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila M. Zipfel
-
Patent number: 10335409Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.Type: GrantFiled: June 11, 2018Date of Patent: July 2, 2019Assignee: Gilead Pharmasset LLCInventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
-
Patent number: 10287311Abstract: The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2?R)-2?-deoxy-2?-fluoro-2?-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.Type: GrantFiled: September 12, 2007Date of Patent: May 14, 2019Assignee: GILEAD PHARMASSET LLCInventor: Jeremy Clark
-
Patent number: 10183037Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.Type: GrantFiled: January 20, 2017Date of Patent: January 22, 2019Assignee: Gilead Pharmasset LLCInventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
-
Patent number: 10100076Abstract: The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.Type: GrantFiled: June 3, 2013Date of Patent: October 16, 2018Assignee: Gilead Pharmasset LLCInventors: Lieven Stuyver, Kyoichi Watanabe
-
Patent number: 10086011Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: August 7, 2017Date of Patent: October 2, 2018Assignee: Gilead Pharmasset LLCInventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
-
Patent number: 10039779Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.Type: GrantFiled: December 29, 2016Date of Patent: August 7, 2018Assignee: Gilead Pharmasset LLCInventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
-
Patent number: 9981955Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: September 28, 2016Date of Patent: May 29, 2018Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Patent number: 9890134Abstract: The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.Type: GrantFiled: April 28, 2017Date of Patent: February 13, 2018Assignee: Gilead Pharmasset LLCInventors: Kevin M. Allan, Shinji Fujimori, Lars V. Heumann, Grace May Huynh, Katie Ann Keaton, Chrisopher M. Levins, Ganapati Reddy Pamulapati, Benjamin James Roberts, Keshab Sarma, Martin Gerald Teresk, Xiang Wang, Scott Alan Wolckenhauer